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Abstract
Background: The number of patients with endometrial carcinoma (EmCa) with advanced stage or high histological grade is
increasing and prognosis has not improved for over the last decade. There is an urgent need for the discovery of novel
molecular targets for diagnosis, prognosis and treatment of EmCa, which will have the potential to improve the clinical
strategy and outcome of this disease.
Methodology and Results: We used a ‘‘drill-down’’ proteomics approach to facilitate the identification of novel molecular
targets for diagnosis, prognosis and/or therapeutic intervention for EmCa. Based on peptide ions identified and their
retention times in the first LC-MS/MS analysis, an exclusion list was generated for subsequent iterations. A total of 1529
proteins have been identified below the ProteinpilotH 5% error threshold from the seven sets of iTRAQ experiments
performed. On average, the second iteration added 78% new peptides to those identified after the first run, while the third
iteration added 36% additional peptides. Of the 1529 proteins identified, only 40 satisfied our criteria for significant
differential expression in EmCa in comparison to normal proliferative tissues. These proteins included metabolic enzymes
(pyruvate kinase M2 and lactate dehydrogenase A); calcium binding proteins (S100A6, calcyphosine and calumenin), and
proteins involved in regulating inflammation, proliferation and invasion (annexin A1, interleukin enhancer-binding factor 3,
alpha-1-antitrypsin, macrophage capping protein and cathepsin B). Network analyses revealed regulation of these
molecular targets by c-myc, Her2/neu and TNF alpha, suggesting intervention with these pathways may be a promising
strategy for the development of novel molecular targeted therapies for EmCa.
Conclusions: Our analyses revealed the significance of drill-down proteomics approach in combination with iTRAQ to
overcome some of the limitations of current proteomics strategies. This study led to the identification of a number of novel
molecular targets having therapeutic potential for targeted molecular therapies for endometrial carcinoma.
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Introduction
Endometrial carcinoma (EmCa) is the fourth most-prevalent
cancerinwomeninNorthAmerica,with42160newcasesand 7780
deaths expected this year in the U.S. alone [1]. There are two major
types of endometrial cancer: Type I EmCa of endometrioid
histology and Type II EmCa which is serous or clear cell in
morphology, the latter type typically being the more aggressive of
the two. Type I EmCa is the common form of endometrial cancer,
constituting about 70–80% of the total cases [2,3]. Diagnosis is
mostly based on histological examination of tissues obtained after a
biopsy, an invasive procedure typically performed as a result of
investigative diagnosis upon abnormal uterine bleeding at presen-
tation. Endometrial carcinomas have been primarily treated by
means of surgery with additional radiation and/or chemotherapy,
and relatively favorable outcomes have been attained provided the
cancers are detected early. However, the number of patients with
EmCa in an advanced stage or high histological grade, which is
indicative of a poor prognosis, is increasing [2,4]. There is an urgent
need for the discovery of novel molecular targets for the diagnosis,
prognosis and treatment of EmCa, which will have the potential to
improve the clinical strategy and outcome of this disease.
Recently, there has been intense interest in the study of global
protein expression, and proteomic approaches appear to present a
new strategy for cancer research and the identification of new
biomarkers for clinical application. Numerous proteomic studies
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cancer biomarkers through differential protein screening using
cancer and non-cancerous tissues [5–9]. One of the most widely
used technologies for biomarker discovery is a bottom-up approach
that involves chemical labeling of peptides resulting from enzymatic
digestion of sample proteins, followed by mixing of the control and
test samples prior to liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) analysis to ensure identical treatment of the
samples [6,7,9]. Among the more common of these labeling
reagents in use currently are the isobaric tags for relative and
absolute quantification (iTRAQ) [10]. Tagging enables distinguish-
ing of otherwise identical peptides originating from individual
samples in the mixture via reporter ions formed from these tags,
which permit relative quantification of the given peptide in the
samples, and thereby the corresponding protein. Due to the
complexity of tissue samples, a pre-fractionation of the samples
using strong cation exchange (SCX) is typically performed, prior to
analytical separation on a nanoscale reverse-phase (RP) column,
which is coupled online with the mass spectrometer. Despite this
two-dimensional chromatographic separation, there is still a
tendency for a large number of peptides to co-elute during the
RP separation because of sample complexity. As a result, the mass
spectrometer is typically only able to examine a fraction of the
peptides due to time constraints. In an automated data acquisition,
the MS software tends to favor analysis of the most abundant
peptides at the expense of co-eluting peptides of lower abundances.
As many cancer-relevant proteins, including signaling and regula-
tory proteins, are typically expressed in low concentrations, this
bottom-up, shotgun approach tends to miss out on acquiring the
most-valuable information[11].A possiblesolutiontothis issueisan
iterative analysis of the same sample, coupled with an exclusion list
of identified peptides that is generated after each run and used to
inform the choice of ions that are targeted for MS/MS analysis
during subsequent runs. This strategy forces the mass spectrometer
to target new, less-abundant peptides for MS/MS analysis during
each successive iteration. Variations of this approach have been
reported for matrix-assisted laser desorption/ionization (MALDI)
MS/MS and ESI-MS/MS [12,13].
In the study, we used an iterative analysis, referred herein as the
‘‘drill down approach’’, to facilitate the identification of novel
molecular targets for diagnosis, prognosis and/or therapeutic
intervention for endometrial cancer. The major objective of this
drill-down method is to unearth more peptides. After the first LC-
MS/MS analysis, the identified peptide ions and their retention
time were added to generate an exclusion list for further iterations
in LC-MS/MS analysis. Our approach is conceptually similar to
the ‘‘selective precursor ion exclusion’’ (sel-PIE) method described
earlier by Wang et al. [11]. To our knowledge, this is the first time
that such a combination of protein quantification using iTRAQ
labeling and iterative analysis approach has been used for
discovery of cancer biomarkers.
Results
Identification of proteins using iterative analysis with
iTRAQ
A total of 1529 proteins have been identified by ProteinpilotH at
a confidence level of 95% from the seven sets of iTRAQ
experiments carried out in this study. The first run of all the
fractions identified a total of 1137 non-redundant proteins, with
the second and third iterations contributing the remaining 392
non-redundant proteins. On average, the second iteration added
78% new peptides to those identified after the first run, while the
third iteration added 36% more peptides as shown in Figure 1 and
Table 1. Within a given set, about 12% of the peptides were
common to any two successive iterations; however, only 3 to 6% of
the peptides were identified in all three iterations. As expected,
these additional peptides improved the coverage of identified
proteins. Indeed, the second iteration added 34% new proteins on
average, while the third iteration added only 14% to the combined
list from iterations 1 and 2; thus there was little incentive to
perform further iterations. 40% of the proteins identified during
the first run were also identified in the next two iterations (Table 1).
Of the 1529 proteins, 623 were identified by a single peptide; 423
of which showed $99% in confidence. The remaining 906
proteins were identified on average with six peptides per protein,
considering only peptides with $95% confidence scores. Of the
1529 proteins identified in this study, 1260 proteins (i.e. 82%) had
iTRAQ ratios reported for EmCa tissue samples. A full list of the
identified proteins and their mean iTRAQ ratios is available in
Table S1. A pie chart showing the distribution in cellular functions
of these proteins is shown in Figure 2.
Identification of differentially expressed proteins in EmCa
To determine differentially expressed proteins that may serve as
potential molecular targets for the evaluation of diagnosis and/or
prognosis of EmCa, all proteins (n=1529) identified in this study
were evaluated using the criteria described in the Material &
Methods section. A list of 40 proteins that may serve as potential
biomarkers for EmCa is shown in Table 2. Of these 40 biomarker
candidates, 38 were identified with a minimum of two peptides.
The two exceptions (S100 calcium-binding protein A6 and beta-2-
glycoprotein 1) were included as they were identified by a peptide
with $99% in confidence, and manual inspection showed
excellent MS/MS spectral quality (Figures S1 and S2). Individual
iTRAQ values for protein quantification are listed in Table S2a; a
list of all identified peptides with a Proteinpilot confidence level
$95% is available in Table S3. Table S4 lists the iterations in the
sample analysis where proteins in Table 2 were quantified. As the
EmCa and normal proliferative tissues were obtained from
different individuals and were, therefore, not identical (i.e., the
analyses were not replicates), the typical concept of standard
deviation in quantitative analysis may be misleading as a measure
of analytical quality. We have, therefore, opted to express the
distributions of combined analytical and individual variability in
Figure 1. Number of unique peptides identified in one or more
iterations, sum of all sets. On average, the second iteration added
78% new peptides to those identified after the first run, while the third
iteration added 36% more peptides. Within a given set, about 12% of
the peptides were common to any two successive iterations; however,
only 3 to 6% of the peptides were identified in all three iterations.
doi:10.1371/journal.pone.0016352.g001
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values deviate within 610% from their means, 54% within 620%,
and 88% within 650% (see Table S2b for details). These
distributions are in support of our hypothesis that a 50% change
in iTRAQ ratios is indicative of differential expression. Indeed, we
identified a group of 16 additional proteins which just missed the
cutoff of our criteria for differential expression and which may yet
qualify after inclusion of additional samples (Table 3).
Evaluation of diagnostic potential of differentially
expressed proteins in EmCa
Other parameters relevant to diagnostic potentials were also
evaluated. These include positive predictive values (PPVs) and
areas under the curve (AUCs) available from receiver operating
characteristics (ROC) analysis. Values for the individual biomark-
er candidates are listed in Table 2.
Verification of differential expression of proteins in EmCa
tissues
The overexpression of selected biomarker candidates: cathepsin
B, calumenin, S100A6, lactate dehydrogenase A (LDHA), and
HNRNPA1 in EmCa tissues were verified by Western blot
analyses in a subset of the same tissue samples used for iTRAQ
LC-MS/MS. Figure 3 shows a comparison of four EmCa tissues
(T) with four normal endometria (N) for the five biomarker
candidates with b-actin serving as a loading control. Furthermore,
immunohistochemical analyses in an independent set of tissue
samples (n=5 each) revealed intense cytoplasmic and/or nuclear
immunostaining of S100A6 protein in tumor cells of endometrioid
EmCa tissue sections (typical results are shown in Figure 4),
whereas no significant immunostaining was observed in the
epithelial cells of normal proliferative endometria.
Network Analysis
We performed Ingenuity Pathway Analysis (IPA) to generate
networks showing direct and indirect regulations/interactions
among proteins identified in this study. These networks show
involvement of key players including TNF alpha, NFkB, c-myc,
Her2/Neu, b-catenin, and Erk1/2 proteins, which regulate
inflammation, and the survival and proliferation of tumor cells
(Figure 5). Most of the molecular targets identified in this study are
regulated by c-myc, Her2/neu, and TNF a, thus suggesting
intervention of these pathways may provide a means to the
development of molecular targeted therapies for endometrial
cancer.
Discussion
There has been considerable recent interest in the identification
of potential cancer markers for diagnosis and prognosis via
differential proteomic analysis. The various issues, pitfalls, and
successes of these proteomics-based biomarker studies have been
discussed and reviewed [14–17]. Our study led to the identifica-
tion of 40 proteins showing significant differential expression in
EmCa in comparison with normal proliferative tissues. These
proteins include metabolic enzymes [pyruvate kinase M2 (PKM2)
and lactate dehydrogenase A (LDHA)]; calcium binding proteins
(S100A6, calcyphosine and calumenin); and proteins involved in
regulating inflammation, proliferation and invasion [annexin A1
(ANXA1), interleukin enhancer-binding factor 3 (ILF3), alpha-1-
antitrypsin (AAT), macrophage capping protein (CAPG) and
Figure 2. Distribution of proteins according to their cellular
functions.
doi:10.1371/journal.pone.0016352.g002
Table 1. Comparison of identified protein numbers across iterative analyses of iTRAQ sets
a.
Total proteins Additional proteins Additional Common
All runs Iter 1 Iter 2 Iter 3
Common to all
iterations Iter 2/1 Iter 3/1+2
Common to all
iterations
Set 1 888 787 40 61 122 5.1% 7.4% 15.5%
Set 2 635 434 122 79 162 28.1% 14.2% 37.3%
Set 3 520 408 14 98 136 3.4% 23.2% 33.3%
Set 4 207 148 51 8 48 34.5% 4.0% 32.4%
Set 5 263 161 49 53 91 30.4% 25.2% 56.5%
Set 6 558 227 265 66 141 116.7% 13.4% 62.1%
Set 7 554 412 81 61 190 19.7% 12.4% 46.1%
Average: 34.0% 14.3% 40.5%
aNumbers correspond to the number of unique proteins identified; percentages refer to new proteins over existing ones.
doi:10.1371/journal.pone.0016352.t001
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receptor (ER) and p53 on expression of these proteins, which
warrants verification of these observations in EmCa tissues on a
larger scale. Among the proteins identified in this study, we have
previously reported altered expression of AAT, CAPG, pyruvate
kinase M1/M2, and creatinase kinase B. Two of these proteins
(pyruvate kinase M2 and creatinase kinase B) have been included
here for consideration, as additional manual investigation of the
data revealed that while the expression ratio changes for these two
proteins were just under 50% (pyruvate kinase M1/M2, 1.43; and
creatinase kinase B, 0.69), they did meet the other two criteria (see
Materials and Methods). Furthermore, an independent study using
immunohistochemistry on a tissue microarray (n=148 patients)
carried by our group demonstrated the remarkable potential of
AAT and PKM2 as diagnostic biomarkers for EmCa [18–20]. It is
noteworthy that increased amount of tumor PKM2 has also been
reported in the tumor cells and EDTA plasma of patients with
cancers of the kidney, lung, breast, cervical and gastrointestinal
Table 2. Mean iTRAQ ratios for potential EmCa molecular targets.
Accession Number Protein Name EmCa tissues Normal tissues p-value PPV AUC
P62851 40S ribosomal protein S25 1.91 1.06 0.01 0.71 0.74
P07108 Diazepam binding inhibitor 1.60 0.97 0.002 0.88 0.81
P23526 Adenosylhomocysteinase 1.62 0.99 0.002 0.80 0.74
P01009 Alpha-1 antitrypsin 0.56 0.99 0.00 0.89 0.85
P02765 Alpha-2-HS-glycoprotein 0.56 0.99 0.01 0.71 0.77
P01023 Alpha-2-macroglobulin 0.59 0.92 0.002 0.75 0.79
O95994 Anterior gradient protein 2 homolog 1.82 1.04 0.025 0.71 0.60
P02647 Apolipoprotein A-I 0.67 0.99 0.025 0.83 0.88
P02652 Apolipoprotein A-II 0.55 0.92 0.025 0.71 0.74
Q15121 Astrocytic phosphoprotein PEA-15 1.98 0.76 0.01 0.80 0.73
P02749 Beta-2-glycoprotein 1 0.50 1.01 0.005 0.67 0.69
Q13938 Calcyphosine 1.60 0.95 0.00 0.89 0.85
O43852 Calumenin (Crocalbin) 0.45 0.93 0.002 1.00 1.00
P07858 Cathepsin B 1.61 1.05 0.002 0.88 0.84
P00450 Ceruloplasmin 0.62 1.12 0.002 0.83 0.86
Q99832 Chaperonin containing TCP1, subunit 7 (Eta) 1.59 0.95 0.025 1.00 0.67
P02452 Collagen, type I, alpha 1 0.52 0.99 0.002 0.73 0.75
P08123 Collagen, type I, alpha 2 0.56 1.02 0.002 0.73 0.81
Q16555 Dihydropyrimidinase-like 2 0.64 1.01 0.00 0.80 0.80
P05198 Eukaryotic translation initiation factor 2 subunit 1 1.90 1.03 0.05 0.83 0.77
P47756 F-actin capping protein subunit beta (CapZ beta) 1.57 0.88 0.005 0.75 0.63
P02671 Fibrinogen alpha chain 0.54 0.89 0.005 0.62 0.65
P02675 Fibrinogen beta chain 0.50 0.93 0.005 0.64 0.71
P02679 Fibrinogen gamma chain 0.36 0.75 0.025 0.75 0.77
P23142 Fibulin-1 0.47 0.97 0.01 0.80 0.73
Q14315 Filamin-C 0.53 0.95 0.025 0.67 0.63
P00738 Haptoglobin 0.58 0.87 0.025 0.75 0.79
P69905 Hemoglobin subunit alpha 0.55 0.93 0.005 0.58 0.60
P19823 Inter-alpha (Globulin) inhibitor, H2 polypeptide 0.56 0.92 0.025 0.67 0.76
Q12906 Interleukin enhancer-binding factor 3 1.79 1.18 0.05 0.75 0.69
P05787 Keratin, type II cytoskeletal 8 1.98 1.01 0.00 1.00 1.00
P40121 Macrophage capping protein (CAP-G) 1.67 0.91 0.00 1.00 1.00
P29966 Myristoylated alanine-rich C-kinase substrate (MARCKS) 0.65 1.08 0.00 1.00 0.87
O94788 Retinal dehydrogenase 2 0.41 0.91 0.00 0.80 0.87
P06703 S100 calcium-binding protein A6 (Calcyclin) 1.56 0.93 0.005 0.83 0.70
Q6FHJ7 Secreted frizzled-related protein 4 0.43 0.72 0.01 0.67 0.77
P50454 Serpin H1 (47 kDa heat shock protein) 0.34 0.96 0.005 0.78 0.80
P02768 Serum albumin 0.54 0.97 0.001 0.80 0.80
P02787 Transferrin 0.56 0.99 0.00 0.80 0.80
P02774 Vitamin D-binding protein 0.58 1.02 0.00 0.86 0.89
doi:10.1371/journal.pone.0016352.t002
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stomach cancer [21]. Thus PKM2 may act as a general indicator
of malignancy, rather than being specific to EmCa. This
association with tumorigenesis in general is, perhaps, understand-
able in light of PKM2’s function [21]. The switch to the M2
isoform of pyruvate kinase in tumor cells is necessary to induce the
Warburg effect. Increased expression of PKM2 contributes to a
metabolic environment that is amenable to cell proliferation under
hypoxic conditions and promotes tumor cell growth [22,23]. Thus,
PKM2 acts as a metabolic sensor, which allows the tumor cell to
adapt its metabolism to variations in the supply of nutrients.
Interestingly, LDHA also showed overexpression in EmCa tissues
in this study, and PKM2 is known to preferentially shuttles
pyruvate to lactate dehydrogenase [24]. Tyrosine phosphorylation
of lactate dehydrogenase facilitates protein binding to PKM2,
thereby channeling the product of pyruvate kinase to lactate [25].
This helps in generating nicotinamide adenine dinucleotide
(NAD
+) required for maintaining high glycolytic flux in tumor
cells. This metabolic conversion makes glycolysis self-sufficient, as
long as elevated glucose uptake is feasible. A high glycolytic rate
provides synthetic intermediates to rapidly proliferating tumor
cells, required to replicate cell biomass and genome at each cell
division [24,26].
Another important group of proteins found to be deregulated in
EmCa tissues includes four calcium-binding proteins: S100A6,
calcyphosine (CAPS), calumenin (CALU), and annexin A1
(Table 2). S100A6 is predominantly a cytoplasmic protein, but
in the presence of Ca
2+, it can associate with the plasma
membrane and the nuclear envelope. Our immunohistochemical
analysis showed cytoplasmic and/or nuclear staining of S100A6,
predominantly in tumor cells of endometrioid EmCa. This is
further supported by the presence of S100A6 protein in the
cytoplasm and nuclei of lung, skin, and pancreatic ductal
adenocarcinoma cells [27–29]. S100A6 plays an important role
Table 3. Additional potential EmCa biomarker candidates
a.
Accession
Number Protein Name
EmCa No. of
samples
b
EmCa mean
iTRAQ ratio
Normal No. of
samples
b
Normal mean
iTRAQ ratio
Q01518 Adenylyl cyclase-associated protein 1 (CAP 1) 5 1.43 7 1.05
P04217 Alpha-1-B glycoprotein 6 0.69 6 1.07
P04083 Annexin A1 10 1.49 10 1.07
O00299 Chloride intracellular channel protein 1 5 1.47 7 1.05
P0C0L4 Complement component 4A 7 0.68 8 1.03
P12277 Creatine kinase B-type 10 0.69 10 1.00
P21333 Filamin A, alpha 10 0.67 10 0.90
P04792 Heat-shock protein beta-1 (HSP 27) 10 0.68 10 0.96
P02790 Hemopexin (Beta-1B-glycoprotein) 5 0.70 7 1.04
P09651 Heterogeneous nuclear ribonucleoprotein A1 8 1.42 9 0.85
P05783 Keratin, type I cytoskeletal 18 9 1.43 6 0.87
P00338 L-lactate dehydrogenase A chain 10 1.45 10 1.01
P19338 Nucleolin (Protein C23) 7 1.42 5 0.85
P14618 Pyruvate kinase isozymes M1/M2 10 1.43 10 1.00
Q8NBS9 Thioredoxin domain-containing protein 5 9 0.70 9 0.99
Q6NUR7 Villin 2 7 1.47 8 1.08
aDifferentially expressed proteins that satisfy all but one criteria described in Material & Method; these proteins all have changes in expression between 40 and 50%, or
expression ratios between 1.4 and 1.5 or between 0.67 and 0.71.
bNumber of samples observed, out of 10.
doi:10.1371/journal.pone.0016352.t003
Figure 3. Verification of over-expression of proteins in EmCa
tissues by Western blot analysis. Equal amounts of proteins (50 mg/
lane) were resolved on 10% sodium dodecyl sulfate (SDS)-polyacryl-
amide gel and then electro-transferred onto polyvinylidene-difluoride
(PVDF) membrane. After blocking, blots were incubated with respective
mouse monoclonal antibody at appropriate dilutions at 4uC O/N.
Membranes were incubated for 2 h at room temperature with
secondary antibody. Protein bands were detected by the enhanced
chemiluminescence method (GE Health Care) on Kodak hyperfilm.
Western blot analysis showed over expression of (i) S100A6, (ii)
calumenin, (iii) cathepsin B, (iv) lactate dehydrogenase A (LDHA), and
(v) heterogeneous protein A1 (HNRNPA1) in endometrial cancer tissues
(T1, T2, T3 and T4) in comparison to normal endometrium (N1, N2, N3
and N4). b-actin served as a loading control showing equal protein
amounts in each lane.
doi:10.1371/journal.pone.0016352.g003
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by regulating functions of several molecular targets, including p53,
b-catenin, annexins, tropomyosin, calponin, calcyclin-binding
protein/Siah-1-interacting protein (CacyBP/SIP), and Hsp90/
Hsp70-organizing protein (Hop) [30–33]. Overexpression of
S100A6 has been associated with poor prognosis in lung, gastric
and pancreatic cancer [27,31,33]. Of the four Ca
2+ regulatory
proteins found to be differentially expressed in this study, only
calcyphosine has previously been reported to be associated with
poor prognosis in EmCa patients [34]. Annexin A1 (ANXA1),
found to be overexpressed in EmCa tissues in this study, is an
endogenous anti-inflammatory protein. Annexins are a family of
Ca
2+/lipid-binding proteins involved in diverse cellular functions,
such as membrane aggregation, inflammation, phagocytosis,
proliferation, and apoptosis [35]. Together, these results suggest
that the calcium-phosphatidylinositol and cyclic AMP cascades
may play an important role in the regulation of cell function,
proliferation, and differentiation in endometrial carcinogenesis.
Notably, our study also indicates an important role of
inflammation regulatory and RNA binding proteins in high-grade
EmCa. Upregulation of the aforementioned annexin A1 together
with downregulation of apolipoproteins, fibrinogens and hapto-
globin suggests suppression of the inflammatory process in tissues
surrounding the tumor. Interleukin enhancer-binding factor 3
(ILF3 or NF90) and heterogeneous ribonucleoprotein A1 (hnRNP
A1) are RNA binding proteins that regulate expression of several
proteins involved in survival and proliferation of tumor cells
[36–38]. Among others, overexpression of serpin H1, F-actin
capping protein subunit beta (CAPZB), macrophage capping
protein (CAPG), villin 2 (EZR), and cathepsin B (CTSB) are
known to promote cell motility and invasion in tumor tissues
[39–42]. Among the potential molecular markers that could aid in
diagnosis or prognosis of EmCa, some such as PKM2, LDHA and
cathepsin B have already been explored for their therapeutic
potential in other cancers. Inhibition of PKM2 and LDHA, using
short interfering RNA (siRNA) or inhibitors, showed reduced cell
proliferation due to induction of oxidative stress resulting in
apoptosis [43–47]. Furthermore, siRNA-mediated downregulation
of PKM2 sensitized lung cancer cells to cisplatin and doxorubicin.
The potential of these proteins to serve as targets for novel
molecular target-based therapies, therefore, needs to be deter-
mined in the context of endometrial cancer as well.
In this study, the drill-down approach improved the number of
proteins identified, although a core set of peptides was detected in
all runs of any given sample. These instances of repeated detection
are attributable to shifts in retention time, peak tailing, multiple
charges, and modifications (e.g., de-amidation and methionine
oxidation). Following the analysis of the first iTRAQ set, we
improved the precision of fraction injection and widened the
exclusion windows for both time and m/z, from 65t o67 min,
and from 100 mDa to 120 ppm, respectively to mitigate some of
these challenges. We chose not to exclude ions based on
differences of charge or modification, as this would have increased
the exclusion list beyond a practical size, and additionally we
reasoned that some redundancy based on differences of charge or
modification may serve to increase the confidence of identification.
Thus the iterative analyses we employed struck a balance between
the depth of analysis and tractability. However, this identification
via multiple peptides meant that the number of identified proteins
probably increased at a slower rate than would have been possible
had we implemented the exclusion of different charge states and
modifications. Interestingly, the total number of proteins identified
in this study were comparable to those identified in our previous
study (1529 versus 1388 proteins, respectively), despite working
here with only half of the amount of starting material (100 versus
200 mg/sample used earlier) [18].
In conclusion, our analysis clearly reveals the significance of
drill-down proteomic approach in combination with iTRAQ in
identifying biomarker candidates for endometrial cancer. This
study successfully reveals novel differentially expressed proteins
that could serve as molecular targets in diagnosis and/or prognosis
of endometrioid EmCa tissues. Some of these proteins exhibit
potentials as molecular targets for therapeutics.
Materials and Methods
Ethics Statement
Endometrial tissues were retrieved from an in-house, dedicated
research endometrial-tissue bank as described earlier [18]. The
collection and use of these materials were approved by the
Research Ethics Boards of York University, Mount Sinai Hospital,
University Health Network, and North York General Hospital.
The samples originated from patients undergoing hysterectomies
or other clinical procedures involving biopsies. All these samples
were obtained after written informed consent by all participants
involved in this study.
Samples and Reagents
Unless stated otherwise, all reagents were available from Sigma-
Aldrich (St-Louis, MO). For this study, endometrioid carcinoma
Figure 4. Immunohistochemistry of S100A6 protein in EmCa tissues and normal endometrium. Immunohistochemical analysis of S100A6
protein was carried out in independent paraffin-embedded tissue sections of endometrial cancer and normal endometrium (n=5 each) as described
in Materials and Methods. Panel shows (a) no immunostaining of S100A6 protein in normal endometrium; (b) endometrial cancer showing
cytoplasmic expression of S100A6 protein; and (c) negative control showing no expression of S100A6 protein.
doi:10.1371/journal.pone.0016352.g004
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um (n=10) were selected. Five of the Type I EmCa tissue samples
were from biopsies that had been examined in our previous study.
For proteomic analysis, tissue samples were obtained from the
mirror-face of the residual block used for histopathological
evaluation by the pathologist. Tissue samples were washed three
times in ,1 mL of phosphate-buffered saline (PBS) with a mixture
of protease inhibitors (1 mM 4-(2-aminoethyl) benzenesulfonyl
fluoride, 10 mM leupeptin, 1 mg/mL aprotinin, and 1 mM
pepstatin) as described earlier [18]. The washed sample was then
homogenized in 0.5 mL of PBS with protease inhibitors using a
hand-held homogenizer, flash-frozen in liquid nitrogen, and stored
at 280uC until use [18]. After retrieval from storage at 280uC,
samples were thawed, clarified by centrifugation, and the protein
concentration was determined using Bradford assay (Bio-Rad,
CA). For all iTRAQ sets, a reference sample comprising a pool of
the ten normal proliferative samples (100 mg lysate from each
tissue) was used. For each experiment, 100 mg of proteins were
digested with trypsin and labeled individually with the appropriate
iTRAQ tag. The assignments of the tags to the sample types were
randomized to minimize any potential bias in labeling efficiency
between the individual versions of the iTRAQ tags. A total of
seven iTRAQ sets were examined, each comprising three of the
total of 20 individual samples – ten EmCa and ten normal
endometria – and the reference pool. Mouse monoclonal
antibodies against calumenin and HNRNPA1 were available from
Abcam, cathepsin B from Calbiochem, and S100A6 from Santa
Cruz Biotech. Rabbit polyclonal lactate dehydrogenase A (LDHA)
was also obtained from Santa Cruz Biotech.
Strong Cation Exchange (SCX) Separation
Each iTRAQ set was separated by SCX using an HP1050
HPLC instrument (Agilent, Palo Alto, CA) with a 2.1-mm internal
diameter x 100-mm-length PolyLC Polysulfoethyl A column
Figure 5. Network analysis. The potential novel molecular targets identified in this study were subjected to pathway analyses using Ingenuity
Pathways Analysis (IPA) software, Version 7.5. The figure shows direct (bold lines) and indirect (dotted lines) regulations (R)/interactions (--) among
the biomarkers identified in this study and other significantly associated proteins. These networks reveal involvement of key proteins including TNFa,
NFkB, c-myc, Her2/Neu, b-catenin, Jnk and Erk1/2 proteins that regulate inflammation, survival and proliferation.
doi:10.1371/journal.pone.0016352.g005
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? pores (The Nest Group,
Southborough, MA) as described previously [18]. Briefly, the
iTRAQ set was diluted with the loading buffer (identical in
composition to Buffer A: 15 mM KH2PO4 in 25% acetonitrile,
pH 3.0) to a total volume of 1.8 mL, and the pH adjusted to 3.0
with phosphoric acid. The solution was then filtered using a 0.45-
mm syringe filter (Millipore, Cambridge, ON, Canada) before
loading onto the column. Separation was performed using a linear
binary gradient over 1 h, plus 30 min of column re-equilibration
(Table 4). As described earlier, Buffer A was identical in
composition to the loading buffer; Buffer B was Buffer A
containing 350 mM potassium chloride; and Buffer C was Buffer
A containing 1 M potassium chloride. Fractions were collected
every 2 min using an SF-2120 Super Fraction Collector (Advantec
MFS, Dublin, CA) after an initial wait of 2 min to accommodate
the void volume. This resulted in a total of 30 SCX fractions per
iTRAQ set. These fractions were dried using speed-vac (Thermo
Savant SC110 A, Holbrook, NY) and re-dissolved in a minimal
volume of 5% acetonitrile in 0.1% formic acid: typically 8 mL for
each fraction No. 6–9, 12 mL for No. 10–13, 16 mL for No. 14–
16, 20 mL for No. 17–19, 25 mL for No. 20–21, and 30 mL for the
last fractions, No. 22–30. Larger volumes in the later fractions
were necessitated by the need to completely dissolve the larger salt
pellets resulting from their correspondingly higher salt contents.
Fractions No. 1–5 were not analyzed as early fractions mostly
contained iTRAQ by-products.
Reverse-Phase (RP) LC-MS/MS
The SCX fractions No. 6–30 of each iTRAQ set were analyzed
by online nano LC-MS/MS using the LC Packings Ultimate
instrument (Amsterdam, The Netherlands) fitted with a 10-mL
sample loop. The autosampler was used in the microliter pick-up
mode. For each sample, 1 mL solution was loaded onto a 5-mm
reverse phase (RP) C18 precolumn (LC Packings) at 25 mL/min
and washed for 4 min before switching the precolumn in line with
the separation column. The separation column used was a 75-mm-
internal diameter x 150-mm-length capillary column (Integrafrit
capillary from New Objective, Woburn, MA) packed in-house
with 3.5-mm C18 beads with 100-A
? pores from Kromasil (Akzo
Nobel/EKA Chemicals inc, NY). The flow rate used for
separation on the RP column was 200 nL/min. Solvent A was
5% acetonitrile in 0.1% formic acid; Solvent B was 95%
acetonitrile in 0.1% formic acid. The solvent gradient is detailed
in Table 5. A new column was used for each iTRAQ set.
Online MS/MS was accomplished on a QSTAR Pulsar hybrid
quadrupole/time-of-flight (QqTOF) tandem mass spectrometer
(Applied Biosystems/MDS SCIEX, Foster City, CA) in informa-
tion-dependent acquisition mode with the scan cycles set up to
perform a 1-s MS scan followed by five MS/MS scans of the five
most-abundant peaks for 2 s each and with a dynamic exclusion
period of 30 s. The performance of the LC-MS/MS system was
evaluated at minimum once every three days by means of a
standard of 80 fmol of bovine serum albumin tryptic digest. Mass
calibration of the TOF analyzer was verified at the same time and
adjusted when necessary.
Protein Identification and iTRAQ Ratio Calculation
MS/MS spectra were processed by the software Proteinpilot
version 2.0.1 (AB SCIEX, Foster City), using the Paragon
algorithm [48] and against a concatenated Swissprot/Panther
database of 66082 distinct human protein entries (132164 entries
after the reversed sequences were added). Protein identification
was performed using a confidence threshold of 95% (Proteinpilot
Unused score $1.31) with MMTS selected as cysteine modifica-
tion, and with the search option ‘emphasis on biological
modifications’ checked.
Proteinpilot measures the height of the reporter ions’ peaks in
the MS/MS spectra and calculates the ratios relative to the
reporter that is designated as the reference. It then applies a
manufacturer-provided value to correct for the isotopic purity of
the labels, as well as a data-dependent, automatically generated
bias value to correct for discrepancies in sample amounts used for
each sample in the set. The individual peptide ratios for each
protein are averaged in log space with only high-confidence
peptides (confidence $95) being used for the calculation of the
overall iTRAQ ratio reported. Quantification is performed
exclusively through the use of unique peptides, thus eliminating
peptides matching more than one protein or common to different
isoforms.
In instances where a group of peptides can be assigned to more
than one protein, Proteinpilot lists the alternative possibilities
under the selected protein identity. In this respect, the peptides are
unique to a group of proteins, with the selected identity being the
representative protein of this group.
Iterative Runs
Usingthe peptidesummaryreportgeneratedbyProteinpilotfora
specific set of samples, the m/z values and RP elution times of the
identified ions (peptides) were imported into the exclusion list of our
acquisition method. A tool in Perl language, developed in-house,
helped in sorting the peptides and removed most of the redundant
entries in the peptide summary report. Tolerance windows were set
at 6120 ppm for m/z and 6720 s for elution time. The dynamic
exclusion list was maintained for a 30-s time window after the first
MS/MS scan at any particular m/z ratio. Initially, we used the
report for the analysis of all 25 fractions to generate a single
exclusion list comprising m/z values of peptides and their elution
times, beforestarting the second iteration.The reportfor the second
iteration of the same fractions was in turn used to generate a second
list that was added to the first exclusion list before the third iteration
was performed. After the second iTRAQ set was analyzed, we
altered the strategy from using all fractions to generate the exclusion
lists to doing so from groups of five fractions. This allowed for a
more efficient process with a second group of five fractions being
Table 4. LC gradient for strong cation exchange separations.
Time Start 2 min. 58 min. 60 min. 65 min. 75 min. 80 min. 90 min.
%B 0% 0% 100% 100% 0% 0% 0% 0%
%C 0% 0% 0% 0% 100% 100% 0% 0%
Buffer A: 15 mM KH2PO4 in 25% acetonitrile, pH 3.0.
Buffer B: Buffer A containing 350 mM KCl.
Buffer C: Buffer A containing 1 M KCl.
doi:10.1371/journal.pone.0016352.t004
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logistic advantage of this approach, which maximized the use of
available mass spectrometer and computer time, the strategy also
limited the time interval between the three RP separations of the
same fraction. This latter feature reduced the risk of a shift in the
elution time due to chromatographic column aging, or worse,
replacement following a column failure. A final data analysis was
performed on the complete series of the 25 data files to generate a
data report encompassing all 25 fractions of each iTRAQ set. The
analysis of all 25 fractions as a single group enhanced the number of
positive identifications and the identification confidence, by
regrouping different peptides of the same protein scattered across
many fractions.
Analysis of differentially expressed proteins in EmCa as
biomarkers
Proteins identified in all runs were matched by accession
numbers; the expression ratios of proteins in each sample were
averaged across different runs and the mean expression ratios of
proteins were evaluated, with the help of a script written in Matlab
(version 7.7.0.471). Statistical analyses for differential protein
expressions in cancerous versus non-cancerous tissue samples were
performed on the basis of the following criteria: (1) Proteins had to
have iTRAQ ratios determined in at least five of the EmCa
samples and five of the normal proliferative samples. (2) The
averages of the iTRAQ ratios for the EmCa samples were $1.5 or
#0.67, and the averages for the normal proliferative samples did
not exceed the thresholds (i.e., 1.5. normal mean .0.67) as
described earlier [18,19,49]. In addition, some underexpressed
proteins in EmCa were accepted provided they were observed at
least three times in the EmCa samples and that all iTRAQ ratios
were #0.67. This modification was adopted to accommodate the
lower chance of determining low-abundance proteins due to the
stochastic nature of MS/MS analysis. These proteins, however,
still had to be observed five or more times in the normal samples
for inclusion. (3) The means of the iTRAQ ratios from the EmCa
and normal proliferative samples were compared using the
Student t-test. Proteins fulfilling all of the above criteria and
exhibiting significant differential expressions according to the t-test
(p#0.05) were considered to be potential biomarkers for EmCa.
The above criteria have proven to work well on a number of
cancers: the majority of biomarker candidates identified subse-
quently verified successfully [18,19,49]. To further evaluate the
significance of these differentially expressed proteins as biomark-
ers, PPVs and AUCs were evaluated by means of ROC analyses as
described earlier [18,50].
Pathway Analysis
Potential novel molecular targets identified in this study
(Tables 2 and 3) were subjected to pathway analyses using
Ingenuity Pathways Analysis (IPA), version 7.5 (Ingenuity Systems,
Redwood City, CA). This software interrogated a proprietary
database of published data to generate protein interaction
networks. The IPA database consists of exclusive ontology
representing 300 000 biologic objects ranging from genes,
proteins, and molecular and cellular processes. More than
11,200 human genes are currently represented in the database.
The proteins were categorized based on location, cellular
components, and reported or suggested biochemical, biologic
and molecular functions using the software. The identified proteins
were then mapped to networks that were generated based on
evidence from existing literature available in the Ingenuity
database and then ranked by score. A score of 3 or higher has a
99.9% confidence level of not being generated by random chance
alone and was used as the cutoff for identifying protein networks.
Western blotting of differentially expressed proteins in
EmCa tissues
Whole-cell lysates from normal endometrium and EmCa tissues
used for iTRAQ analysis was used for verification of cathepsin B,
calumenin, S100A6, lactate dehydrogenase A (LDHA), and
HNRNPA1 proteins. Equal amounts of proteins (50 mg/lane)
were resolved on 10% sodium dodecyl sulfate (SDS) polyacryl-
amide gel. The proteins were then electro-transferred onto
polyvinylidene difluoride (PVDF) membrane (BioRad, Hercules,
CA). After blocking with 5% non-fat powdered milk in Tris-
buffered saline (TBS, 0.1 M, pH=7.4), blots were incubated with
respective mouse monoclonal antibody at appropriate dilutions at
4uC overnight. The abundance of b-actin (mouse monoclonal
antibody, Cell Signaling Tech.) served as a control for protein
loading in each lane. Membranes were incubated with secondary
antibody, horseradish peroxidase-conjugated mouse/rabbit anti-
IgG (BioRad, CA), diluted at an appropriate dilution in 1% bovine
serum albumin, for 2 h at room temperature. After each step, blots
were washed three times with Tween (0.1%)-TBS. Protein bands
were detected by the enhanced chemiluminescence method (GE
Health Care) on Amersham hyperfilm [50].
Immunohistochemical analysis of S100A6 in normal
endometrium and EmCa tissues
Paraffin-embedded sections (4 mm) of human normal endome-
trial tissues and Type I endometrial cancer (n=5 each) were
collected on snow-coat slides. In brief, the sections were
deparaffinized in xylene, hydrated in gradient alcohol, and pre-
treated in a microwave oven for 15 min at maximum power in
citrate buffer (0.01 M, pH=6.0, 0.5% Tween-20) for antigen
retrieval. The sections were incubated with hydrogen peroxide
(0.3% v/v) in phosphate buffer saline (PBS) for 15 min to quench
the endogenous peroxidase activity, followed by blocking with 5%
fetal bovine serum to preclude non-specific binding. Thereafter,
the slides were incubated with mouse monoclonal anti-S100A6
antibody (sc-52948, 1:50 dilution, Santa Cruz Biotechnology, CA)
for 16 h at 4uC. The primary antibody was detected using the
streptavidin-biotin complex with the Dako LSAB plus kit (Dako
Cytomation, Glostrup, Denmark) and diaminobenzidine as the
chromogen as described earlier by us [50]. All procedures were
Table 5. LC gradient for on-line reverse phase separations.
Time Start 5 min. 10 min. 120 min. 140 min. 145 min. 155 min. 157 min. 189 min.
%B 5% 5% 10% 35% 60% 80% 80% 5% 5%
Solvent A: 5% acetonitrile in 0.1% formic acid.
Solvent B: 95% acetonitrile in 0.1% formic acid.
doi:10.1371/journal.pone.0016352.t005
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were washed three times using TBS with 0.025% Triton-X after
every step. Finally, the sections were counterstained with Mayer’s
hematoxylin and mounted with DPX mountant. In the negative
control tissue sections, the primary antibody was replaced by
isotype specific non-immune mouse IgG. The sections were
evaluated by light microscopic examination.
Supporting Information
Figure S1 MS/MS spectrum of peptide LQDAEIAR
from protein S100-A6.
(TIF)
Figure S2 MS/MS spectrum of peptide VCPFAGILEN-
GAVR from beta-2 glycoprotein 1.
(TIF)
Table S1 Protein average iTRAQ ratios and t-test results.
(XLS)
Table S2 Individual iTRAQ ratios of biomarker candi-
dates. Average ratios per sample: C= endometrial carcinoma,
N= normal proliferative endometrium. The proteins from the
tables S2a and S2b here were reported in Tables 2 and 3 in the
article, respectively.
(XLS)
Table S3 Confidence of identified peptides. A - Identified
peptides whose Proteinpilot confidence was greater than 95%.
Proteins identified by a single peptide were sorted on top of the
table. #Occurences = number of times a particular peptide has
been identified over all sample sets. At the bottom of this table,
summary of the number of peptides per proteins. B - Identified
peptides whose Proteinpilot confidence was greater than 99%.
(XLS)
Table S4 Samples in which each protein from Table 2
has been identified.
(XLS)
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